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The pH-selective insertion and folding of a membrane peptide,
pHLIP [pH (low) insertion peptide], can be used to target acidic
tissue in vivo, including acidic foci in tumors, kidneys, and inflam-
matory sites. In a mouse breast adenocarcinoma model, fluores-
cently labeled pHLIP finds solid acidic tumors with high accuracy
and accumulates in them even at a very early stage of tumor
development. The fluorescence signal is stable for >4 days and is
approximately five times higher in tumors than in healthy coun-
terpart tissue. In a rat antigen-induced arthritis model, pHLIP
preferentially accumulates in inflammatory foci. pHLIP also maps
the renal cortical interstitium; however, kidney accumulation can
be reduced significantly by providing mice with bicarbonate-
containing drinking water. The peptide has three states: soluble in
water, bound to the surface of a membrane, and inserted across
the membrane as an -helix. At physiological pH, the equilibrium
is toward water, which explains its low affinity for cells in healthy
tissue; at acidic pH, titration of Asp residues shifts the equilibrium
toward membrane insertion and tissue accumulation. The replace-
ment of two key Asp residues located in the transmembrane part
of pHLIP by Lys or Asn led to the loss of pH-sensitive insertion into
membranes of liposomes, red blood cells, and cancer cells in vivo,
as well as to the loss of specific accumulation in tumors. pHLIP
nanotechnology introduces a new method of detecting, targeting,
and possibly treating acidic diseased tissue by using the selective
insertion and folding of membrane peptides.
cancer targeting  imaging  peptide insertion
Many pathological conditions such as cancer, ischemic stroke,inflammation, atherosclerotic plaques, and others are asso-
ciated with increased metabolic activity and hypoxia resulting in an
elevated extracellular acidity (1–6). Hypoxia and acidity have
emerged as important factors in tumor biology and responses to
cancer treatment. Imaging of hypoxic and acidic regions could
provide new information about disease localization and progression
andmight enhance diagnosis and therapy. Here we describe the use
of a peptide, pHLIP [pH (low) insertion peptide], to selectively
accumulate in and label acidic tissues. We previously reported that
the pHLIP bionanosyringe, a 36-aa peptide derived from the
bacteriorhodopsin C helix, has three states: soluble in water, bound
to the surface of a membrane, and inserted across the membrane
as an-helix. At physiological pH thewater-soluble form is favored,
whereas at acidic pH the transmembrane -helix predominates
(Fig. 1a) (7). We show that at low pH, pHLIP can translocate
cell-impermeable cargomolecules that are disulfide-linked to the C
terminus across a cell membrane, where they are released in the
cytoplasm by reduction of the disulfide bond (8, 9). Among the
successfully translocated molecules are organic dyes, phalloidin (a
polar, cyclic peptide), and a 12-mer peptide nucleic acid.
Results
We applied the technique of near-infrared (NIR) fluorescence
imaging to follow the ability of fluorescently labeled pHLIP and its
variants to accumulate in tissue with low extracellular pH by using
mouse cancer and rat inflammatory arthritis models. Light with
wavelengths in theNIR range (700–900 nm) can propagate through
tissue for distances on the order of multiple centimeters because of
low tissue and water absorption in that range. NIR fluorescence
imaging offers unique advantages for the imaging of pathophysio-
logic states and is well suited to studies of small animals, tissues,
organs, and whole bodies (10–12). NIR fluorescent dyes were
conjugated with Cys or Lys residues placed on the pHLIP N
terminus, which remains outside of the cell when the peptide inserts
across the lipid bilayer (8). Two different fluorescent probes (Cy5.5
or Alexa750) were used in the study to exclude any possibility of
specific accumulation of a particular dye in the tissue. Alexa750
absorbs and emits at longer wavelengths than does Cy5.5 and has
different physicochemical properties.
Three imaging systems with different imaging capabilities were
used in the study: a homemade imager, an Odyssey IR scanner
(Li-Cor, Lincoln, NE), and a Kodak FX In Vivo Image Station
(Eastman Kodak, New Haven, CT). The homemade imager con-
sists of a light source (150-W xenon lamp) with double fiber-optic
gooseneck, NIR-CCD camera, and filters, allowing us to perform
surface imaging. However, the IR scanner with a variable focal
distance (up to 4 mm) and extremely sensitive recording system
consisting of avalanche diodes allowed us to collect light from the
interior of the body with great sensitivity. An FX Kodak in vivo
image station was used to obtain both fluorescence and x-ray
images.
pHLIP-NIR dye constructs injected into mice bearing breast
adenocarcinoma show significant accumulation in tumors (Fig. 1b),
even very small ones (Fig. 1c). Injection of fluorescent pHLIP and
tumor imaging were performed 4–21 days after cancer-cell implan-
tation to mimic various stages of tumor development from early to
advanced. pHLIPwas given as a single i.p. injection into the left side
of mice with breast adenocarcinoma in their right flanks. pHLIP-
fluorescent dyes were redistributed and concentrated in tumors
within 20 h after injection (Fig. 1d). pHLIPwas able tomark tumors
of various sizes (Fig. 1 e–h), even those that were visually unde-
tectable. A small fluorescent spot is clearly observed in the location
of the tumor-cell injection (Fig. 1e), and a visible tumor appeared
at the location of the fluorescence after several days.
As anothermodel of low pH,we used a rat inflammatory arthritis
model. Arthritis was induced in the right knee joints by using
methylatedBSAandFreund’s complete adjuvant (13). The arthritis
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in this model is induced by inflammatory activity and associated
with the acidification of soft tissue and synovial fluid (14, 15). First,
whole-body imaging was performed (data not shown). The animals
then were killed, and their right and left legs were imaged sepa-
rately. Then, skin and muscle were removed from the legs followed
by fluorescence imaging of the knee joints. pHLIP-Cy5.5 targets
sites of inflammation in the right leg with no accumulation in the
left (control) leg (Fig. 1i). The right leg, and especially the knee
joints, were analyzed. A substantial fluorescence signal (4–5 times
higher than in the left knee joints) was detected in the right knee
joints (Fig. 1i, 1 and 2). The results of whole-body fluorescence
imaging indicate that pHLIP is stable enough to reach and accu-
mulate in the acidic environment associated with various patho-
logical processes.
To check the specificity of pHLIP accumulation in tumors and
test the molecular mechanism of pHLIP insertion, we designed two
peptide variants (N-pHLIP and K-pHLIP):
Y pHLIP: ACEQNPIYWARYADWLFTTPLLLLDLALLVD-
ADEGTG
Y N-pHLIP: ACEQNPIYWARYANWLFTTPLLLLNLALLV-
DADEGTG
Y K-pHLIP: ACEQNPIYWARYAKWLFTTPLLLLKLALLV-
DADEGTG.
In N-pHLIP and K-pHLIP, Asn and Lys replaced Asp residues,
one of which is protonated at low pH and drives pHLIP insertion
(7–9). The interactions of pHLIP and its variants with lipid bilayers
were studied by using liposomes, human red blood cells (RBCs),
and cancer cells in amousemodel. Fluorescence of twoTrp residues
located in the transmembrane part of the peptides is sensitive to the
insertion process (7) and can be used to monitor it. Insertion is
accompanied by the translocation of Trp fluorophores from the
hydrophilic aqueous solution into the hydrophobic environment of
a lipid bilayer, resulting in enhancement of emission and a shift of
the spectrum to short wavelengths (16) (Fig. 2a). Formation of
-helical secondary structure is monitored by using changes in the
circular dichroism (CD) signal (Fig. 2b). It was previously demon-
strated by polarized FTIR that the orientation of pHLIP is per-
pendicular to the lipid bilayer at low pH (7), which is part of the
evidence for a transmembrane -helix.
Unlike pHLIP, K-pHLIP does not show secondary structure
changes between normal and low pH in the presence of liposomes.
However, K-pHLIP is more aggregated in solution (the position of
maximum of the fluorescence spectrum is shifted to short wave-
lengths) than pHLIP and exhibits partial -helical structure at
normal pH in the absence of liposomes. In contrast to the other
peptides, N-pHLIP forms -helical structure in the presence of
liposomes over a wide pH range (4.0–8.0). Trp fluorescence and
CD spectra indicate that K-pHLIP remains outside of the mem-
brane at all pH levels studied, whereas N-pHLIP is mostly in the
membrane.
To further study the interaction of the peptides with amembrane,
we performed experiments on human RBCs. As an important
experimental measure, it was essential to test whether pHLIP
damages RBCs when it is injected into the bloodstream. The lytic
response of pHLIP was measured spectrophotometrically by the
amount of released hemoglobin from human RBCs. Human RBCs
incubated in isotonic buffers at pH 6.0 and 7.4 at room temperature
served as negative controls. As a positive control of 100% lysis,
human RBCs were opened by incubation with 10% Triton X-100
for 1 h at room temperature. The results indicate that pHLIP does
not lyse RBCs at concentrations up to 10 M.
Next, we characterized the effect of pHLIP on RBC membrane
morphology. The RBC has a very flexible membrane, consisting of
a plasmamembrane attached to an intricate membrane skeleton. It
is well known that various agents interacting with RBCs canmodify
the biconcave discoid shape (discocyte; Fig. 2c) of these cells (17,
18). Selective insertion of molecules into the outer leaflet of RBCs
leads to an increase in the relaxed area difference between the two
leaflets of the plasma membrane bilayer, resulting in the formation
of convex structures on the cell surface (e.g., echinocytic spicules;
Fig. 2c) (19–21). The interaction of pHLIP with RBCs at normal
pH (7.4; when the peptide attaches to the cell surface without the
formation of any elements of secondary structure) results in the
appearance of spicules on the surface of 67% of the cells (Fig. 2d
and Table 1), showing extra area occupied by pHLIP on the outer
leaflet of the lipid bilayer. However, a significantly reduced number
of spikes were seen (87% of cells have a smooth, biconcave discoid
shape) when pHLIP was inserted into the membrane at low pH
(6.0), consistent with insertion across both halves of the bilayer.
K-pHLIP induces formation of echinocytes at both normal and low
pH (57%and 55%of cells, respectively), suggesting that the peptide
weakly binds to the membrane surface at both pH levels. N-pHLIP
does not induce significant shape changes inRBCs at normal or low
pH (74% and 83% of the cells, respectively, are discocytes).
Fig. 1. Imaging tumors and inflammation. (a) The mechanism of pHLIP
interaction with lipid bilayers. The peptide has three states: soluble in water,
bound to the surface of a membrane (at normal pH 7.4), and inserted across
the membrane as an -helix (at low pH). (b) Overlay of pHLIP-Cy5.5 fluores-
cence and light images of mice bearing a tumor (7 mm in diameter, 12 d after
106 cell implant) in the right flank obtained on the homemade imager (i.p.
injection of 500 g/kg of pHLIP-Cy5.5 1 d before imaging). (c) pHLIP-Alexa750
fluorescent image (excitation 750 nm, emission 800 nm, artificial green color)
of mice bearing a tumor (2 mm in diameter 6 d after 106 cell implant) in the
right flank obtained on the IR scanner with focal distance set at 3 mm, which
allows for the collection of light from the interior of the body (i.p. injection of
300 g/kg of pHLIP-Alexa750 1 d before imaging). Reflectance is denoted in
red (excitation 680 nm). (d) pHLIP-Cy5.5 given as a single i.p. injection (200
g/kg) into the left side of mice initially diffused into the left flank, but 20 h
later it accumulated in a tumor on the right flank. The fluorescent image of the
back part of each mouse is presented. Blue color represents the background
fluorescent signal, and the red color represents a high intensity of the fluo-
rescence signal. (e–h) Overlay of pHLIP-Cy5.5 (500 g/kg) fluorescence and
light images of back part of mice bearing tumors of different sizes in right
flanks: (e) undetectable by eye at time of imaging 5 d after 105 cell implant,
( f) 3  4 mm (8 d after 106 cell implant), (g) 5  6 mm (12 d after 106 cell
implant), (h) 8 9 mm (18 d after 106 cell implant). (i) Accumulation of pHLIP-
Cy5.5 (2 days after i.p injection, 30 g/kg) in inflammation sites is shown by
overlay of pHLIP fluorescence and photo images of rat right (arthritis) and left
(control) legs. The arthritis was induced in the right leg by injection of
methylated BSA and Freund’s complete adjuvant (the left knee of the rat
received a sham injection of saline and was used as a control). A substantial
fluorescence signal (4–5 times higher than in the left knee joint) was detected
in the right knee (1), especially in the knee joint (2) (red color represents high
fluorescence intensity).
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Fluorescence and CD data indicate that N-pHLIP interacts with
lipid vesicles and forms -helical structure at both pHs. The RBC
data support the idea that N-pHLIP inserts in lipid bilayers as a
transmembrane-helix, whereas the positively chargedLys residues
prevent insertion of K-pHLIP into the hydrophobic core of the lipid
bilayer at both normal and low pH levels. The dramatic RBC shape
changes induced by pHLIP at normal pH and their absence at low
pH are in agreement with the mechanism seen in lipid vesicles.
The ability of pHLIP and its variants to find a tumor and
accumulate in it at very early stages of tumor development was
evaluated in vivo. To create slow-growing tumors, 5 104 JCmouse
breast adenocarcinoma cells were injected s.c. in the right flanks of
mice. Tumors became visible in 16–18 days (1–3 mm in diameter).
pHLIP was able to detect such slow-growing tumors on day 6. Fig.
2e shows NIR images of mice with early tumors 1 day after the i.p.
injection of Cy5.5 alone, pHLIP-Cy5.5, K-pHLIP-Cy5.5, and N-
pHLIP-Cy5.5. Two weeks later, tumors of similar size and shape in
the right flanks became visible in all mice. The accumulation of dye
alone or of the pHLIP variants in tumors was insignificant in
comparison with pHLIP. It is interesting to note that the back-
ground signal from K-pHLIP was very weak, and the peptide was
cleared rapidly from the mouse. The fluorescence signal from
N-pHLIP was significant at the injection site and its vicinity, and it
remained there for a long time, consistent with its local insertion in
membranes. The imaging data in vivo confirm the proposed mo-
lecular mechanism of pHLIP action and show the ability of pHLIP
to target tumors at very early stages of their development.
We examined the level of pHLIP accumulation in tumors. Fig. 3a
shows 3D NIR emission intensity presentations of images of a
tumor (4  5 mm in size) site taken during the 8 days after
pHLIP-Cy5.5 injection. The height (z axes) and intensity of red
color indicate the strength of the NIR signal in the right flank of a
mouse in which the tumor was implanted. The fluorescence signal
was very strong and stable for 4 days, approximately five times
higher in tumors in comparison with the healthy counterpart tissue
[see values of the contrast index (CI) in Fig. 3c]. In previous studies,
accumulation in a tumor was considered substantial if the CI values
were in the range of 2.5–3.5 (for 100 l of 60 M of peptide-dye
injection) (22). Our data show that pHLIP is stable enough to
persist in tumors. Insertion in the cell membrane may protect the
peptide from attack by proteases, allowing it to accumulate in
tumor tissue in significant amounts.
Where else does pHLIP accumulate besides the tumor? We
collected organs and tissues on the second day after injection of the
pHLIP-NIR dye (Fig. 3 b and d). Whole-body fluorescence images,
as well as fluorescence of individual organs, indicate that pHLIP
accumulates in tumors and the kidney, the latter being a major site
in the catabolism of low-molecular-weight proteins and having
acidic regions. Buffering the feed water to pH 8.2 results in an
elevation of the renal tubular and cortical interstitial pH (23).
Indeed, we observed a significant reduction (50%) of the fluo-
rescent signal in the kidneys of mice fed with water at pH 8.2 (Fig.
3e), supporting the idea that low pH causes the observed imaging.
pHLIP allowed us to map the acidic areas in the kidney.
Experiments with pHLIP consisting of L-amino acids and D-
amino acids gave similar results: accumulation in tumor, inflam-
matory foci, and kidney. The results confirm that themechanism of
peptide insertion is the formation of a transmembrane -helix, a
process that does not depend on amino acid chirality. Interestingly,
Fig. 2. Interaction of pHLIP and its variants with membranes of liposomes, human RBCs, and cancer cells in vivo. Trp fluorescence (a) and CD (b) spectra of pHLIP
[consisting of L–amino acids (solid lines) and D-amino acids (dotted lines)], K-pHLIP, and N-pHLIP were recorded to monitor the process of their interaction with
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine liposomes at normal and low pH. The fluorescence excitation wavelength was 295 nm for the excitation of Trp
fluorophores. The concentrations of peptides and lipids were 5 and 600M, respectively. Black signifies fluorescence and CD spectra of pHLIP at pH 8.0 in the absence
of liposomes; blue, after 30 min of incubation with liposomes at pH 8.0; red, after incubation with liposomes at pH 4.5. (c) Binding of various agents selectively to the
outer leaflet of RBCs can change the biconcave discoid shape of the cells (left image) into convex structures on the cell surface (right image), echinocytic spicules. (d)
Phase-contrast images of 1% suspensions of human RBCs incubated for 15 min with 5 M pHLIP, K-pHLIP, and N-pHLIP at pH 7.4 and 6.0 are presented. RBCs without
peptides had normal discoid shape at both pH 7.4 and 6.0 (images are not shown). Statistical data (percentage of cells having spicules) are shown in Table 1. To avoid
induction of echinocytosis by proximity to a glass surface, glass slides were treated with 2% dimethyldichlorosilane in 1,1,1-trichloromethane for 10 min and rinsed with
methanol, ethanol, and water and allowed to dry before use in experiments. Grace Bio-Labs (Bend, OR) CoverWell imaging chambers were used for observation of
RBC/peptide suspensions instead of glass coverslips. The pictures were taken on an Olympus IX71 inverted-fluorescence microscope with an100 objective. (e) Overlay
of NIR fluorescence and x-ray images obtained by using a Kodak In-Vivo FX image station on the next day after i.p. injection of 500g/kg pHLIP-Cy5.5, K-pHLIP-Cy5.5,
N-pHLIP-Cy5.5, or molar equivalent amount of Cy5.5 alone on mice bearing tumors in the right flank. The injection of peptide was performed when the tumor was
not detectable by eye on the sixth day after cancer-cell implantation (5  104 cells); imaging was performed on the next day. Tumors became visible 2 weeks later.
Replacement of two key Asp residues located in the transmembrane part of pHLIP by Lys or Asn leads to the loss of pH-sensitive insertion into membranes of liposomes,
RBCs, and cancer cells in vivo, as well as to the loss of specific accumulation in tumors.
Table 1. Human RBCs were used to probe the interaction of
pHLIP and its variants with lipid bilayers at various pH levels
pH
RBCs,
%
RBCs  pHLIP,
%
RBCs  K-pHLIP,
%
RBCs  N-pHLIP,
%
7.4 14.3  5.8 67.3  12.6 57.3  8.9 25.8  4.1
6.0 16.2  6.2 12.6  4.0 55.5  7.3 17.1  5.9
The percentage of RBCs having spicules on the surface was calculated from
the phase-contrast images of 1% suspensions of human RBCs incubated for 15
min with 5 M pHLIP, K-pHLIP, and N-pHLIP at pH 7.4 and 6.0. A high
percentage of spicule formation is interpreted as a visualization of the inter-
action of peptides with the outer leaflet of RBCs, which leads to an increase in
the relaxed area difference between the two leaflets of the plasma membrane
and consequent distortion of the biconcave discoid shape of the cells.
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the distribution of pHLIP consisting of D-amino acids differs from
the distribution of L-pHLIP, with more accumulation in tumors
and/or less renal uptake, possibly as a result of better stability of the
D-peptide in blood and/or less uptake by kidney. We also observed
pHLIP accumulation in the skin, perhaps from the irritation caused
by shaving the mice before imaging experiments to remove the
background from hair fluorescence. We assume that skin uptake
will be significantly less in nonshaved animals, which could lead to
increased values in the CI.We did not observe strong accumulation
of fluorescently labeled pHLIP in the liver.
A preliminary toxicity study was carried out on 4-week-old
female and male mice. L-pHLIP and D-pHLIP were injected
intravenously at the maximum concentration of 4 mg/kg, and
animals were monitored for 2 months. No physiological or behav-
ioral changes were detected.
Discussion
Acidity characterizes the environment of cells that are partially
starved for oxygen, such as highly proliferative cancer cells or
macrophages at sites of inflammation and infection.Almost all solid
tumors develop an acidic environment, known as the Warburg
effect (Nobel Prize, 1931). The pHLIP bionanosyringe technology
allows us to target and map acidity in vivo, which provides an
opportunity for selective delivery of diagnostic or therapeutic
agents to the sites of diseases. At physiological pH, the soluble form
of pHLIP is favored, whereas at acidic pH the transmembrane
-helix predominates. The pHLIP affinity formembranes at lowpH
(5.0) is 20 times higher than that at high pH (8.0) (Y.K.R., M.S.,
O.A.A., andD.M.E., unpublished data).Wehave shown that, at low
pH, pHLIP can translocate cell-impermeable cargo molecules that
are disulfide-linked to the C terminus across a cell membrane,
where they are released in the cytoplasm by reduction of the
disulfide bond (8, 9). Among the successfully translocated mole-
cules are organic dyes, phalloidin (a polar, cyclic peptide), and
12-mer peptide nucleic acids. Neither the entry of pHLIP into the
membrane nor the translocation of molecules into cells is mediated
by endocytosis, binding to cell receptors, or formation of pores in
cell membranes. Rather, entry and translocation result from the
formation of a helix across the lipid bilayer because of the increase
of peptide hydrophobicity associated with the protonation of an
Asp residue at low pH. The replacement of two key Asp residues
located in the transmembrane part of pHLIP by Lys or Asn led to
the loss of pH-sensitive membrane insertion into liposomes and
RBCs in vitro and cancer cells in vivo and, consequently, to the loss
of specific accumulation in tumors. We show that in a mouse breast
adenocarcinoma model, fluorescently labeled pHLIP finds solid
acidic tumors with high accuracy and accumulates at very early as
well as advanced stages of tumor development. The fluorescence
signal is stable for days and is approximately five times higher in
tumors than in the healthy counterpart tissue. The pHLIP persis-
tence stands in contrast to low-molecular-weight compounds, which
typically wash out of the body in minutes. This property of pHLIP
would allow hours of data collection from positron emission
tomography (PET) or MRI agents to obtain excellent contrast
ratios. Recently, we tested the distribution of a PET-imaging probe
1,4,7,10-tetraazacyclotetradecane-N,N,N,N-tetraacetic acid
(DOTA) covalently attached to the N terminus of pHLIP in male
athymic mice bearing LNCaP tumors. DOTA-pHLIP afforded
excellent tumor visualization in LNCaP tumor-bearing mice when
using small-animal PET. Tumor/muscle ratios (standardized up-
take value) were 6 at 24 h. pHLIP also accumulates in compa-
rable amounts in the kidney, which is not surprising because the
kidney is a major site in the catabolism of low-molecular-weight
proteins and has acidic regions. However, the uptake can be
reduced significantly by providing mice with bicarbonate-buffered
drinking water at pH 8.0 and perhaps by using the D-amino acid
peptide. We did not observe a significant accumulation of pHLIP
in the liver or other organs. pHLIP is not toxic for cells (8, 9), and
preliminary studies suggest that it is not toxic for mice.
Recent developments have allowed the study of gene signatures
of many cancer cells. The data indicate that a number of genes are
up- and down-regulated in cancer, making it problematic to rely on
any single tumor biomarker even for one type of cancer (24),
whereas the physiological properties of the microenvironment of a
majority (90%) of tumors, such as hypoxia, acidity, and changes in
temperature, are considered promising environmental markers for
tumor targeting (25, 26). Hypoxia and acidosis are hallmarks of
tumors at both very early and advanced stages of tumor develop-
Vavere, A. L., Andreev, O. A., Engelman, D. M., Reshetnyak, Y. K., Lewis, J. S. (2007) 17th
International Symposium on Radiopharmaceutical Sciences (International Symposium on
Radiopharmaceutical Sciences, Aachen, Germany), abstract.
Fig. 3. CI and distribution of pHLIP in organs. (a) The 3D
presentation of NIR fluorescence images of mice bearing a
tumor (4 5 mm size) 8 days after i.p. injection of 500 g/kg
of pHLIP-Cy5.5, which was done on the seventh day of tumor
growth. The height (z axes) and intensity of red color indi-
cate the strength of the NIR signal in the right flank of a
mouse where the tumor was implanted. (b) NIR fluorescence
and light images of kidneys (1 a and b), tumor (2), skin (3),
stomach cleaned and separated into 2 parts (4), liver (5),
muscle (6), lung (7), spleen (8), heart (9), and brain (10)
collected from a mouse bearing a tumor on the next day
after injection of 500 g/kg of pHLIP-Cy5.5 consisting of
L-amino acids or D-amino acids. (c) The CI, which indicates
the relative strength of the fluorescence signal in tumors,
was calculated as a ratio: CI 	 [(Fltumor 
 Flauto)/(Flnorm 

Flauto)]. Fltumor and Flnorm are the mean fluorescence inten-
sities of tumor and normal contralateral regions of the same
area, respectively, and Flauto is the autofluorescence from
the corresponding region measured before injection. The
fluorescence signal from the tumor was approximately five
times stronger in comparison with the contralateral region.
The CI was calculated for 20 animals. (d) The fluorescence
signals were measured from organs collected the next day
after i.p. injection of 500 g/kg of pHLIP-Cy5.5 consisting of
L-amino acids and D-amino acids. The signals were normalized to the intensity of kidney fluorescence. (e) The NIR fluorescence of kidney 2 days after i.p.
injection of 500 g/kg of pHLIP-Alexa750 into mice fed with regular water (Left) and 80 mM NaHCO3 (pH 8.2) solution (Right) obtained on the IR scanner.
The alkalinization resulted in an 50% reduction of pHLIP accumulation in the kidney.
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ment. At hypoxic and acidic regions, chemotherapy and radiation
therapies are significantly less effective (27). Moreover, recent data
reveal the importance of inflammatory processes, which are asso-
ciated with an elevated level of acidity, in tumor progression and
even development (28, 29). Inflammatory mechanisms account for
many features of various pathological processes such as rheumatoid
arthritis or atherosclerotic plaque formation (30). Therefore, de-
tection of an acidic environment might reveal possible sites of such
diseases. pHLIP nanotechnology offers an approach for mapping
areas of elevated acidity in the body, possibly enabling the study of
pathological processes, diagnosis of diseases, treatment by delivery
of molecules to affected areas, and monitoring of therapeutic
outcomes.
Methods
Synthesis and Labeling of Peptides. All peptides were prepared by
solid-phase peptide synthesis using standard Fmoc (9-fluorenylm-
ethyloxycarbonyl) chemistry and purified by reverse-phase chro-
matography (on a C18 column) at the W. M. Keck Foundation
Biotechnology Resource Laboratory at Yale University. The pep-
tide sequences used were:
Y pHLIP: ACEQNPIYWARYADWLFTTPLLLLDLALLVDA-
DEGTG
Y K-pHLIP: ACEQNPIYWARYAKWLFTTPLLLLKLALLV-
DADEGTG
Y N-pHLIP: ACEQNPIYWARYANWLFTTPLLLLNLALLV-
DADEGTG.
We also synthesized a peptide with the same sequence as pHLIP
from D-amino acids. The peptides were labeled with Cy5.5 (Am-
ersham Bioscience) or Alexa750 (Invitrogen) according to supplier
protocols. Free dyes were removed on Sephadex G-10 spin col-
umns. The concentration and degree of labeling of peptides were
determined by absorbance at 280 nm, 674 nm (Cy5.5), and 750 nm
(Alexa750) with corrections for contributions of dyes at 280 nm
according to supplied protocols. Molar extinction coefficients were
used: peptide 280 	 13,940 M
1cm
1; Cy5.5 674 	 250,000
M
1cm
1; and Alexa750 750	 240,000 M
1cm
1. Peptide purity
was checked by Tricine [N-tris(hydroxymethyl)methylglycine] SDS/
PAGE followed by scanning gels on an IR scanner (Odyssey). The
labeled peptides were stored at 
80°C.
Liposome Preparation. Large unilamellar vesicles were prepared by
extrusion. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(Avanti Polar Lipids, Inc.) in chloroform was evaporated on a
rotary evaporator and dried under vacuum for several hours. The
phospholipid film was rehydrated in 10 mM phosphate buffer (pH
8.0), vortexed for 2 h, and passed through 100-nm pores in the
extruder 15 times. The concentration of the lipids was calculated by
light scattering on aPC1 spectrofluorometer (ISS, Inc., Champaign,
IL) with the set of excitation and emission monochromators at 700
nm and a vertical orientation of the excitation and emission
polarizers. The scattering signal of the liposomes consisting of
nonfluorescent lipids was compared with the signal of a known
concentration of liposomes containing 1% phospholipids with
fluorescently labeled head groups (phosphatidylethanolamine lis-
samine rhodamine B) prepared by exactly the same method de-
scribed above.
Purification of Human RBCs from Whole Blood. Fresh whole human
blood (tested negative for hepatitis B virus, hepatitis C virus, HIV1,
HIV2, human T-lymphotrophic virus types 1 and 2, and syphilis)
with sodium heparin was obtained from Bioreclamation (Hicks-
ville, NY) and stored at 4°C. RBCs were purified within 48 h of
withdrawal from human donors. Human RBCs were initially iso-
lated by centrifugation at 600 g for 20min at 4°C. After removing
the plasma and buffy layers by suction, the red cell pellet was
resuspended in cold isotonic buffer containing 145 mM NaCl, 5
mM KCl, and 5 mM Hepes (pH 7.4) by trituration and then
re-centrifuged at 2000  g for 10 min at 4°C. The RBCs were
washed with the isotonic buffer a total of four times to completely
remove the plasma and buffy layers. The washed RBCs were
resuspended in cold isotonic buffer (pH 7.4) to an approximate
hematocrit level of 50% and stored at 4°C. All RBC samples were
used for analysis within 24 h of purification and storage at 4°C.
Human RBC Lysis Assay. Cell lysis by pHLIP was measured spectro-
photometrically by the amount of released hemoglobin fromhuman
RBCs. Samples of human RBCs were prepared at 1%, 5%, and
10%hematocrits in isotonic buffer containing 145mMNaCl, 5mM
KCl, and 5 mM Hepes at pH 6.0 and pH 7.4. pHLIP, purified
separately in isotonic buffer at pH 6.0 and pH 7.4, was added to the
human RBC suspensions at 1%, 5%, and 10% hematocrits at final
concentrations of 1, 5, and 10M.AllRBC samples were incubated
at the various pHLIP concentrations for 1 h at room temperature.
The samples were centrifuged at 2,000 g for 10 min at t	 1 min,
10 min, 30 min, and 1 h, and aliquots of the supernatant were
collected. Absorption of the supernatant was recorded at 414 nm.
Measurement of the absorption at 414 nm in comparison to 540 nm
results in a 10-fold increase in the sensitivity of the assay (31).
Human RBCs incubated in isotonic buffers at pH 6.0 and pH 7.4
at room temperature served as negative controls. As a positive
control of 100% lysis, human RBCs were lysed with 10% Triton
X-100 for 1 h at room temperature. Percent hemolysis at 1%, 5%,
and 10%hematocrits and pHLIP concentrations of 1, 5, and 10M
was calculated as
100 100
A100% A
A100% A0%
, [1]
where A is the absorption measured at 414 nm.
Tumor Mouse Model. Female C3D2F1 mice ranging in age from 4
to 6weeks andweighing from14 to 16 gwere obtained fromCharles
River Laboratories. The mice weighed20 g at the time of peptide
injection. Murine breast adenocarcinoma (CRL-2116) cell lines
from the American Type Culture Collection were cultured in
DMEM supplemented with 10% FBS, 100 units/ml penicillin, 0.1
mg/ml streptomycin, and 2 mM glutamine in a humidified atmo-
sphere of 5% CO2 and 95% air at 37°C. Cancer cells were grown
to 70% confluence and then harvested and resuspended in L-15
medium. Mouse tumors were established by s.c. injection of breast
cancer cells (105 to 107 cells per flank per 0.1 ml) in the right flank
of adult female C3D2F1 mice.
Arthritis Rat Model. Male Lewis rats that ranged in age from 7 to 8
weeks and weighed from 180 to 200 g were obtained from Harlan
Labs (Indianapolis, IN). The rats weighed 300 g at the time of
peptide injection. Arthritis was induced in the right femorotibial
joint of rats as described previously (12, 13). Briefly, on two
occasions 2 weeks apart, the joint was injected s.c. with an emulsion
(1.0 ml) of an equal mixture of BSA (methylated BSA) (0.5 mg;
Sigma–Aldrich) and Freund’s complete adjuvant (0.25 mg of My-
cobacterium tuberculosis; Sigma–Aldrich). Six days after the second
injection, 50 g of methylated BSAwas injected into the right joint.
The left knee joints of the rats received a sham injection of saline
and were used as controls. The progression of inflammation was
monitored by measuring the diameters of the right and left knee
joints by using a micrometer. Beginning 1 week and lasting for the
duration of 1 month after the induction of arthritis, the mean
diameter of the right joints was significantly (P 0.001) higher than
that of the left joints, highlighting the inflammatory process in the
right leg. Student’s unpaired 2-sample t test was used to test for
differences in measurements between the right and left knee joints.
P values of 0.02 were considered significant. After whole-body
Andreev et al. PNAS  May 8, 2007  vol. 104  no. 19  7897
BI
O
PH
YS
IC
S
imaging, the animals were killed, skin and muscle were removed
from their legs, and fluorescence imaging was performed.
Fluorescence and CD Measurements. Trp fluorescence and CD
measurements were carried out on a PC1 ISS spectrofluorometer
and a Jasco (Easton, MD) 810 spectropolarimeter at 25°C, respec-
tively, in phosphate buffer with adjusted pH. The concentrations of
peptides and lipids used in this study were 5 and 600 M, respec-
tively. The excitation wavelength was 295 nm to limit the excitation
to only Trp fluorophores in the peptides. The fluorescence spectra
were recorded from 310 to 400 nm with the spectral widths of
excitation and emission slits set at 4 and 2 nm, respectively. The
polarizers in the excitation and emission paths were set at the
‘‘magic’’ angle (54.7° from the vertical orientation) and vertically
(0°), respectively, to reduce Wood’s anomalies from the reflecting
holographic grating. The emission spectrum of an aqueous solution
of L-Trp was used as a standard for the correction of protein spectra
for the instrument spectral sensitivity. The intensities of the cor-
rected spectra are proportional to the number of photons emitted
per unit of time of indicated wavelength interval.
Light Microscopy of RBCs.WashedRBCs were prepared fromwhole
human blood within 48 h of withdrawal from human donors
(described above). A series of 1%, 5%, and 10% suspensions of
washed human RBCs were made at pH 7.4 and 6.0 in isotonic
buffers containing 145mMNaCl, 5mMKCl, and 5mMHepes. The
RBC suspensions were then incubated in Eppendorf tubes for 15
min with 5 MpHLIP, K-PHLIP, and N-pHLIP at pH 7.4 and 6.0.
Control RBC samples at pH 7.4 and 6.0 were then monitored for
shape changes via light microscopy in addition to the RBC/peptide
samples at pH 7.4 and 6.0. Samples were placed in Grace Bio-Labs
CoverWell imaging chambers on glass slides that were treated with
2% dimethyldichlorosilane in 1,1,1-trichloromethane for 10 min
and rinsed with methanol, ethanol, and water and allowed to dry
before use in experiments to prevent the glass effect from inducing
artificial echinocytosis. All samples were monitored via phase-
contrast microscopy by using an Olympus IX71 inverted-
fluorescence microscope with an 100 objective and via differen-
tial interference contrast microscopy by using a Leitz Diaplan light
microscope with Nomarski optics and an100 objective (data not
shown).
NIR Fluorescence Imaging of Whole Body, Tissue, and Organs. Mice
were injected with fluorescent pHLIP and imaged 4–21 days after
cancer-cell implantation to mimic various stages of tumor devel-
opment from early to advanced. When possible, tumor size was
measured with a caliper. In some cases, at earlier stages, tumors
were not visible by eye but were detectable by fluorescence imaging
and later became visible. The inflammation sites in rats were
imaged 20–30 days after induction of arthritis. The various amounts
(100–200 l of 5–50 M) of different types of pHLIP labeled with
Cy5.5 or Alexa750 were given as a single i.v. or i.p. injection to
animals. Before imaging ofmice or rats, their hair was removedwith
Nair (Carter-Wallace, New York). As a control, the free dyes
incubated for several days inL-15mediumwere injected at the same
concentrations into mice carrying tumors. Incubation in L-15 was
necessary to decrease the chemical reactivity of maleimide or
NHS-ester moieties of dyes by their covalent binding to Cys or Lys
amino acids, respectively, which are present in the L-15 solution. To
increase the pH in the renal system, some mice were exposed to
drinking water containing 80 mMNaHCO3 (pH 8.2) for 7–14 days.
The imaging was performed while the animal was under anesthesia
with a mixture of ketamine (90 mg/kg) and xylazine (9 mg/kg).
Three imaging systems were used as our studies progressed: a
homemade system with a light source (150-W xenon lamp) and
double fiber-optic gooseneck [Dolan-Jenner Industries (Boxbor-
ough, MA) illuminator], an NIR-CCD camera (Hitachi, Tokyo),
and appropriate filters (Omega Optical, Brattleboro, VT); an IR
scanner (Odyssey); and a Kodak imaging station. To evaluate the
signal/noise ratio of fluorescence images we calculated CI values
according to that described by Jiang et al. (22). For the determi-
nation of tumor contrast, fluorescence mean, maximum, and
minimal values of intensity, the SD and area of tumor and corre-
sponding healthy tissue area were calculated by using NIH Image
software and the area-of-interest function. The CI was measured
according to the formula CI	 [(Fltumor
 Flauto)/(Flnorm
 Flauto)],
where Fltumor and Flnorm are the fluorescence mean intensities of
tumor and normal contralateral region of the same area, respec-
tively, and Flauto is the autofluorescence from the corresponding
region measured before injection. To evaluate the uptake of
fluorescent peptides by internal organs and tissues, mice were
dissected at various times after the injection of peptides.Organs and
tissues were collected and their fluorescence wasmeasured by using
the homemade imager (each sample was measured separately by
using the same set of optical parameters) or the IROdyssey scanner
(all samples were scanned at the same time).
All animal studies were conducted in accordance with the
principles and procedures outlined in the National Institutes of
HealthGuide for theCare andUse ofAnimals. Approvals from the
Institutional Animal Care and Use Committee at the University of
Rhode Island were obtained before initiation of the study.
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